Wang L, Elhanafi S, Storm AC, Topazian MD, Majumder S, Abu Dayyeh BK, Levy MJ, Petersen BT, Martin JA, Chari ST, Vege SS, and Chandrasekhara V
Background: Endoscopic intervention for pancreatic fluid collections (PFCs) with disconnected pancreatic duct syndrome (DPDS) has been associated with failures and increased need for additional endoscopic and non-endoscopic interventions. The primary aim of this study was to determine the outcomes of endoscopic ultrasound (EUS)-guided transmural drainage of PFCs in patients with DPDS., Methods: In patients undergoing EUS-guided drainage of PFCs from January 2013 to January 2018, demographic profiles, procedural indications and details, adverse events, outcomes, and subsequent interventions were retrospectively collected. Overall treatment success was determined by PFC resolution on follow-up imaging or stent removal without recurrence., Results: EUS-guided drainage of PFCs was performed in 141 patients. DPDS was present in 57 of them (40 %) and walled-off necrosis was the most frequent type of PFC (55 %). DPDS was not associated with lower clinical success, increased number of repeat interventions, or increased time to PFC resolution. Patients with DPDS were more likely to be treated with permanent transmural plastic double-pigtail stents (odds ratio [OR] 6.4; 95 % confidence interval [CI] 2.5 - 16.5; P < 0.001). However, when stents were removed, DPDS was associated with increased PFC recurrence after stent removal (OR 8.0; 95 %CI 1.2 - 381.8; P = 0.04)., Conclusions: DPDS frequently occurs in patients with PFCs but does not negatively impact successful resolution. DPDS is associated with increased PFC recurrence after stent removal., Competing Interests: Dr. Abu Dayyeh is consultant for Metamodix, BFKW, DyaMx, Boston Scientific, USGI medical, and Endo-TAGSS. He received research support from Apollo Endosurgery, USGI, Spatz Medical, Boston Scientific, GI Dynamics, Cairn Diagnostics, Aspire Bariatrics, and Medtronic. He served as a speaker for Johnson and Johnson, Endogastric Solutions, and Olympus. Bret T Petersen: 3M: Stock Shareholder; Abbvie: Stock Shareholder; Boston Scientific: Grant/Research Support, Consulting; Exact Sciences: Stock Shareholder; GIE Medical: Consulting; Johnson & Johnson: Stock Shareholder; Medtronic: Stock Shareholder; Olympus America: Consulting. Andrew C Storm: Apollo Endosurgery: Consulting; Boston Scientific: Grant/Research Support; Endo-TAGSS: Grant/Research Support; Enterasense: Grant/Research Support; GI Dynamics: Consulting. Santhi S Vege: Uptodate: Royalties; vical: Consulting. Vinay Chandrasekhara – Consultant, Interpace Diagnostics. Shareholder, Nevakar Corporation. The other authors declare that they have no conflict of interest., (Thieme. All rights reserved.)